NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
LEXINGTON, Mass., May 25, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients with advanced solid tumors or lymphomas at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from June 2-6 in Chicago.
In addition, researchers from the Dana-Farber Cancer Institute and Boston Children’s Hospital will be presenting information on an investigator-initiated Phase 1 multicenter trial using CUDC-907, Curis’ proprietary drug candidate, to treat children and young adults with relapsed or refractory solid tumors, CNS tumors and lymphoma.
Additional information on the presentations can be found below and can be accessed at www.am.asco.org.
CA-170 Poster Presentation:
| Date/Time: | Monday, June 5, 8 AM — 11:30 AM CDT |
| Abstract Number: | TPS3099 |
| Presentation Title: | Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas |
CUDC-907 Poster Presentation:
| Date/Time: | Sunday, June 4, 8 AM — 11:30 AM CDT |
| Abstract Number: | TPS10576 |
| Presentation Title: | Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma |
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
